Aldeyra Therapeutics, Inc. (ALDX): Cash & Equivalents
$70.04M
As of 2025-12-31
-21.4%
3-year compound annual growth
-2.1%
5-year compound annual growth
+16.9%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $70.04M | +28.5% | 2026-02-27, Balance as of period end |
| 2024-12-31 | $54.53M | n/a | 2026-02-27, Balance as of period end |
| No annual figure between 2022-12-31 and 2024-12-31. | |||
| 2022-12-31 | $144.42M | -37.2% | 2024-03-07, Balance as of period end |
| 2021-12-31 | $229.79M | +195.1% | 2023-03-09, Balance as of period end |
| 2020-12-31 | $77.86M | +75.3% | 2022-03-17, Balance as of period end |
| 2019-12-31 | $44.43M | -6.2% | 2021-03-11, Balance as of period end |
| 2018-12-31 | $47.36M | +136.5% | 2020-03-12, Balance as of period end |
| 2017-12-31 | $20.02M | +66.7% | 2019-03-08, Balance as of period end |
| 2016-12-31 | $12.02M | -18.0% | 2018-03-29, Balance as of period end |
| 2015-12-31 | $14.65M | +71.8% | 2017-03-30, Balance as of period end |
| 2014-12-31 | $8.53M | +161.4% | 2016-03-30, Balance as of period end |
| 2013-12-31 | $3.26M | n/a | 2015-03-23, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Aldeyra Therapeutics, Inc. (ALDX) | 2025-12-31 | $70.04M | +28.5% |
| Incannex Healthcare Inc. (IXHL) | 2026-06-30 | $67.71M | +350.2% |
| Corvus Pharmaceuticals, Inc. (CRVS) | 2025-12-31 | $4.58M | -47.6% |
| Inovio Pharmaceuticals, Inc. (INO) | 2025-12-31 | $44.27M | -32.7% |
| Werewolf Therapeutics, Inc. (HOWL) | 2025-12-31 | $57.05M | -48.6% |
| Spero Therapeutics, Inc. (SPRO) | 2025-12-31 | $40.27M | -23.9% |
| Context Therapeutics Inc. (CNTX) | 2025-12-31 | $66.00M | -30.1% |
| Cumberland Pharmaceuticals Inc (CPIX) | 2025-12-31 | $11.44M | -36.3% |
| Grace Therapeutics, Inc. (GRCE) | 2026-03-31 | $16.98M | -23.3% |
Compare ALDX, IXHL, CRVS, INO side by side · Screen every company in Pharmaceutical Preparations ↗